Biotech Insider Buying: Insys Therapeutics (NASDAQ:INSY), Corcept Therapeutics Incorporated (NASDAQ:CORT), Durata Therapeutics (NASDAQ:DRTX), Celsion Corporation (NASDAQ:CLSN), Biota Pharmaceuticals (NASDAQ:BOTA)

Insys Therapeutics Inc (NASDAQ:INSY) Director John N. Kapoor bought 20,000 shares of the stock in a transaction dated Thursday, June 12th. The stock was purchased at an average cost of $24.84 per share, with a total value of $496,800.00. Following the completion of the acquisition, the director now directly owns 15,991 shares in the company, valued at approximately $397,216.Insys Therapeutics Inc (NASDAQ:INSY) net profit margin is 36.90% and weekly performance is 2.76%. On last trading day company shares ended up $26.45. Analysts mean target price for the company is $52.50. Insys Therapeutics Inc (NASDAQ:INSY) distance from 50-day simple moving average (SMA50) is -18.73%.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Director G Leonard Baker, Jr. purchased 103,386 shares of Corcept Therapeutics stock on the open market in a transaction dated Wednesday, June 11th. The shares were purchased at an average cost of $2.32 per share, with a total value of $239,855.52. Following the acquisition, the director now directly owns 578,389 shares in the company, valued at approximately $1,341,862.Corcept Therapeutics Incorporated (NASDAQ:CORT) shares fell -6.94% in last trading session and ended the day on $2.28. Gross Margin is 97.70% and its return on assets is -71.70 %. Corcept Therapeutics Incorporated (NASDAQ:CORT) quarterly performance is -38.21%.

Durata Therapeutics Inc (NASDAQ:DRTX) CEO Paul R Edick purchased 3,000 shares of Durata Therapeutics stock in a transaction dated Thursday, June 12th. The shares were purchased at an average price of $ 15.23 per share, for a total transaction of $ 45,690.00. Durata Therapeutics Inc (NASDAQ:DRTX) shares moved up 2.93% in last trading session and was closed at $16.16, while trading in range of $15.50 – $16.19. Durata Therapeutics Inc (NASDAQ:DRTX) year to date (YTD) performance is 26.35%.

Celsion Corporation (NASDAQ:CLSN) CEO Michael H Tardugno purchased 5,000 shares of Biota Celsion Corporation stock in a transaction dated Wednesday, June 11th. The shares were purchased at an average price of $ 3.20 per share, for a total transaction of $ 16,000.00.Celsion Corporation (NASDAQ:CLSN) ended the last trading day at $3.44. Company weekly volatility is calculated as 5.53% and price to cash ratio as 1.38. Celsion Corporation (NASDAQ:CLSN) showed a positive weekly performance of 12.05%.

Biota Pharmaceuticals Inc (NASDAQ:BOTA) CEO Russell H. Plumb purchased 32,031 shares of Biota Pharmaceuticals stock in a transaction dated Wednesday, June 11th. The shares were purchased at an average price of $2.99 per share, for a total transaction of $95,772.69. Following the acquisition, the chief executive officer now directly owns 127,579 shares in the company, valued at approximately $381,461.Biota Pharmaceuticals Inc (NASDAQ:BOTA) net profit margin is -19.60% and weekly performance is 33.88%. On last trading day company shares ended up $3.24. Analysts mean target price for the company is $5.00. Biota Pharmaceuticals Inc (NASDAQ:BOTA) distance from 50-day simple moving average (SMA50) is -15.95%.